Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
64.7M
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
26.9M
-
Shares change
-
+26.9M
-
Total reported value, excl. options
-
$1.28B
-
Value change
-
+$1.28B
-
Number of buys
-
61
-
Price
-
$48.02
Significant Holders of Zentalis Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (ZNTL) as of Q2 2020
61 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share as of Q2 2020.
Zentalis Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (ZNTL) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26.9M shares
of 64.7M outstanding shares and own 41.49% of the company stock.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (4.44M shares), Matrix Capital Management Company, LP (3.82M shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (2.66M shares), FMR LLC (2.31M shares), Redmile Group, LLC (1.66M shares), CITADEL ADVISORS LLC (1.56M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.19M shares), PERCEPTIVE ADVISORS LLC (1.05M shares), FARALLON CAPITAL MANAGEMENT LLC (991K shares), and EVENTIDE ASSET MANAGEMENT, LLC (915K shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.